Girish Dhall

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · The Lancet Oncology · 2019 · 502 citations · Full text

Medicine, Oncology, Pediatrics +16

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

Roberto Chiarle, William J. Simmons, Honjying Cai et al. · Nature Medicine · 2005 · 436 citations

Medicine, Cancer Biology, Oncology +12

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors

Roberto Chiarle, Jerald Z. Gong, Ilaria Guasparri et al. · Blood · 2003 · 247 citations · Full text

Veterinary Medicine, Oncology, Pathology +15

Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols

Girish Dhall, Howard Grodman, Lingyun Ji et al. · Pediatric Blood & Cancer · 2008 · 240 citations · Full text

Medicine, Oncology, Pediatrics +13

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

Matthias A. Karajannis, Geneviève Legault, Michael J. Fisher et al. · Neuro-Oncology · 2014 · 219 citations · Full text

Medicine, Oncology, Radiology +17